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Introduction 
Acute kidney injury (AKI) is described as a sudden and 
prolonged decrease in glomerular filtration rate. AKI is 
induced by various reasons including low blood volume 
from any cause, exposure to substances harmful to the 
kidney, and urinary tract obstruction. Tubular necrosis 
and apoptosis, changes of the filtration barrier, 
glomerular misfiltration, vasoconstriction and tubular 
obstruction, interstitial swelling and activation of 
proteolytic enzymes characterize the injury.1-3 AKI has 
been reported in 5 to 7% of hospitalized patients and 
over 30% of ICU hospitalized patients. The mortality 
rate of patients with AKI is about 50% and in cases in 
which dialysis is needed the mortality rate could reach 
88%.4 Therefore, AKI has attracted much research 
interests in recent years because of its significant 
mortality rate. 
A novel strategy for treatment of AKI is MSC 
transplantation. Promising results of preclinical studies, 
ease of handling and enormous expansion potential of 
MSCs, and encouraging preliminary clinical trials of 
MSC transplantation in other diseases, have made the 
MSC based approaches very interesting for the treatment 
of human kidney injury.5,6 According to numerous 
studies, MSCs exert their repairing effects on kidney via 
two important mechanisms including repopulation and 
paracrine actions.6-8 
The pathogenesis of AKI is complex, however, it has 
been shown that ischemia/reperfusion triggers AKI, 
mainly via aggravating stresses, inflammation and 
activation of renin–angiotensin system (RAS).9 Hypoxia, 
serum deprivation and oxidative stress are important 
factors in the pathogenesis of AKI.
10-12
 As mentioned 
before, MSC transplantation could treat AKI; however, 
the most important problem with the application of 
MSCs for the treatment is their low survival rate in such 
a stressful microenvironment. Therefore, protection of 
MSCs against various stresses is very important for 
improving their therapeutic potential. 
The nuclear factor erythroid-2 related factor 2 (Nrf2) is a 
critical transcription factor for protection of cells against 
numerous stresses.13,14 When cells are challenged by 
various stresses, the Nrf2 induces the transcription of 
diverse antioxidant and detoxification enzymes which 
eventually play important roles to ameliorate oxidative 
stress-induced injuries in the cells.15-18 Previously, in an 
in vitro study we showed that Nrf2 potentiates MSCs for 
combating with various stresses.19 Moreover, recent 
studies have shown that Nrf2 over-expression increases 
the secretion rate of some growth factors such as VEGF, 
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Abstract 
Purpose: Recent developments in the field of cell therapy have led to a renewed interest in 
treatment of acute kidney injury (AKI). However, the early death of transplanted 
mesenchymal stem cells (MSCs) in stressful microenvironment of a recipient tissue is a 
major problem with this kind of treatment. The objective of this study was to determine 
whether overexpression of a cytoprotective factor, nuclear factor erythroid-2 related factor 2 
(Nrf2), in MSCs could protect rats against AKI.  
Methods: The Nrf2 was overexpressed in MSCs by recombinant adenoviruses, and the 
MSCs were implanted to rats suffering from cisplatin-induced AKI.  
Results: The obtained results showed that transplantation with the engineered MSCs 
ameliorates cisplatin-induced AKI. Morphologic features of the investigated kidneys showed 
that transplantation with the MSCs in which Nrf2 had been overexpressed significantly 
improved the complications of AKI.  
Conclusion: These findings suggested that the engineered MSCs might be a good candidate 
to be further evaluated in clinical trials. However, detailed studies must be performed to 
investigate the possible carcinogenic effect of Nrf2 overexpression. 
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which might enhance the AKI improvement.20,21 We 
hypothesized that Nrf2 overexpression in MSCs might 
exert beneficial therapeutic effects on the cells which 
could result in their higher survival rate against cisplatin 
induced stresses, and repairing much tissue than the non-
recombinant MSCs by their differentiation to kidney 
cells and/or secretion of growth factors. Hence, we 
transiently over-expressed Nrf2 in rat MSCs using an 
adenoviral transduction system, and then transplanted the 
cells to cisplatin-induced AKI rats. Then, we assayed 
that whether improvement rate of the AKI is higher 
following transplantation of the Nrf2 over-expressing 
MSCs comparing to non-manipulated control MSCs. 
 
Materials and Methods 
MSC isolation and identification 
For isolation of MSCs, rats were anesthetized with 
ketamine (40mg/kg) and xylazine (10mg/kg). Then, 
femurs and tibias of both legs were dissected out and 
cleaned under sterile operating conditions. Afterward, 
the marrow cavity was exposed by cutting the spongious 
end of each bone. We followed the process as described 
above. MSCs were characterized by adhesion capacity 
and differentiation assays. All experiments were 
performed on cells after the third passage. 
 
Nrf2 isolation and construction of recombinant 
adenovirus  
Gateway pAd/CMV/V5-DEST vector and ViraPower 
Adenoviral Expression System (Invitrogen) were used to 
construct recombinant adenoviruses, as described 
elsewhere.19 Briefly, the human MSCs were UV 
irradiated for one hour, and then subjected to RNA 
extraction using TriPure isolation reagent (Roche). 
Afterwards, full-length Nrf2 cDNA was obtained 
through RT-PCR using specific primers. Then, the 
amplified cDNA fragment was cloned into 
pENTER/TEV/DTOPO vector using pENTER 
Directional TOPO Cloning kit (Invitrogen). Following 
confirmation of the cloned sequence, the Nrf2 expression 
cassette was transferred from pENTR gateway vector to 
the adenovirus expression plasmid pAd/CMV/V5-DEST 
(Invitrogen) and designated as pAd/CMV-Nrf2. To 
obtain virus particles, the recombinant pAd/CMV-Nrf2 
plasmid was transfected to 293A cells. As a control, 
pAd/CMV/V5-GW/lacZ vector (Invitrogen) was 
transfected into 293A cells to produce lacZ-bearing 
adenoviruses. After infection of rat MSCs with the 
recombinant adenovirus, the expression of Nrf2 was 
evaluated with RT-PCR analyses. 
 
In vitro cytotoxic effect of cisplatin on surveillance of 
Nrf2-MSCs 
The cytotoxic effect of cisplatin on the rat MSCs was 
determined by MTT assay.19,22 Briefly, 2×104 rat 
MSCs/well were seeded in a 96-well plate and 
appropriate MOIs of the recombinant or control 
adenoviruses were added to the cells after 12 h. Six days 
post transfection, cisplatin was added to the wells at 
various concentrations of 0-250µg/ml, (Sigma, 
Germany) and after 48h, the cells were subjected to 
cytotoxicity assay. In this regard, 3-(4,5-dimethlthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, 
Dusseldorf, Germany) was added to the cells at final 
concentration of 0.5 mg/ml and incubated at 37°C in a 
5% CO2 atmosphere for 4 h. Finally, the reaction was 
stopped by addition of 10% SDS and 0.01 M HCl and 
the absorbance was read at 570 nm. 
 
Animal model of AKI 
Male Wistar rats (2 months old, 200-250 g) were 
obtained from Pasteur Institute of Iran. Animal care and 
experiments were according to the National Institute of 
Health’s Guide for the Care and Use of Laboratory 
Animals. For induction of acute kidney injury, rats were 
given an intraperitoneal injection of cisplatin (5 mg/kg 
body wt). One day after receiving the cisplatin injection 
(day 1), the rats were divided into three groups of 10 
animals, each received an intravenous injection as 
follows: (1) control group, which received 0.5ml normal 
saline; (2) Ad-MSCs group, which received 2×106 cells 
infected with control adenoviruses; (3) Nrf2-MSCs 
group, which received 2 ×106 cells infected with Nrf2 
bearing adenoviruses. Blood samples for assessment of 
blood urea nitrogen (BUN) and determination of 
creatinine concentration were collected before the 
cisplatin dose (baseline) and in surviving rats on days 3, 
6, 8 and 11 of the experiment. For determination of renal 
function, and histology and morphometric analysis, the 
rats were sacrificed on day eleven after the cisplatin 
injection.  
For morphologic analysis with light microscopy, kidney 
specimens were fixed in formaldehyde and paraffin 
sections of 5µm thickness were stained with hematoxylin 
and eosin. Then, the luminal hyaline casts and tubular 
necrosis (cell debris in tubular lumen, denudation of 
tubular basement membrane and nuclear fragmentation) 
were assessed in non-overlapping fields (up to 30 for 
each section) using 40x objective (high-power field). 
Sections were analyzed by a same pathologist, in a 
single-blind manner. 
 
Statistical Analysis 
The statistical significance of the results was evaluated 
using analysis of variance, ANOVA, and a Student’s t-
test. In all tests, p < 0.05 was considered significant. 
 
Results  
Adenoviral-mediated gene delivery to MSCs 
Recombinant adenovirus production results have been 
presented in our recent article.19 In a few words, Human 
MSCs were characterized by their adhesion to tissue 
culture surfaces, immunophenotyping and differentiation 
capacities. Nrf2 was isolated from human MSCs and 
cloned into pENTR/D-TOPO. Subsequently, the fidelity 
of the cloned sequence was confirmed by sequencing 
(GenBank accession number HM446346). Finally, 
recombinant adenoviruses were constructed in 293A 
 |    203 
Nrf2-MSCs protected rats against AKI
Advanced Pharmaceutical Bulletin, 2015, 5(2), 201-208 
cells. Our results showed that Nrf2 over-expression by 
adenovirus system is transient and its expression level 
increased to the highest at day 6. 
 
Nrf2 protects MSCs against cisplatin induced-toxicities 
in vitro 
To determine whether human Nrf2 can protect bone 
marrow derived MSCs against cisplatin induced 
cytotoxicity; the Nrf2 expressing cells were exposed to 
various concentrations of cisplatin and then subjected to 
cytotoxicity assay. As it is represented by Figure 1, the 
rat MSCs infected with Nrf2-adenoviruses were more 
resistant to 150µg/ml cisplatin comparing to the controls. 
This confirmed the protective effect of Nrf2 on MSCs 
against cisplatin induced toxicities. 
 
 
Figure 1. Evaluation of cytotoxicity of various cisplatin 
concentrations on rat MSCs. (Mean±SE, **: P<0.01) 
 
Nrf2 improves efficacy of MSCs transplantation in 
animal model of cisplatin induced toxicity 
To evaluate whether Nrf2-MSCs exert in vivo protective 
effects against cisplatin induced toxicity, acute kidney 
injury was induced in rats by cisplatin administration, an 
antitumor drug whose clinical use is accompanied by a 
high incidence of nephrotoxicity, mainly in the form of 
renal tubular damage. Under light microscope, the 
kidneys with induced cisplatin toxicity showed AKI-
associated tubular lesions including loss of brush border, 
flattening and loss of the epithelial cells, luminal cell 
debris and hyaline casts. In addition, renal function tests 
(BUN and creatinine) showed significant increase 
(Figure 2). However, in the Ad-MSCs group, intravenous 
injection of Ad-MSCs strongly protected renal function 
as reflected by significantly lower amount of BUN and 
creatinine concentration comparing to the control group 
which only received normal saline. Furthermore, tubular 
necrosis and cast formation decreased significantly. 
Moreover, in the last group, administration of Nrf2-
MSCs promoted much more functional and histological 
improvement. This confirmed the successful function, 
surveillance and resistance of Nrf2-MSCs in the reactive 
oxygen species (ROS)-rich microenvironment induced 
by cisplatin (Figure 3).  
 
 
Figure 2. Protective effects of Nrf2 on MSCs following their 
transplantation in rats suffering from cisplatin-induced acute kidney 
injury. A; Assessment of renal function by measuring BUN values. 
B; Evaluation of serum creatinine concentrations as an indicator of 
renal function (Mean±SE, **: P<0.01 and ***: P<0.001). 
 
 
Figure 3. Renal histology following transplantation of Nrf2-MSCs 
and Ad-MSCs. A, B and C; Light microscopy images of renal 
tissue from rats (H&E stained kidney sections, 400×). A; Cisplatin 
group: tubules showed extensive and marked changes consisting 
of flattening, loss of epithelial cells and brush border. B; Ad-MSC 
group: less severe tubular damage and very mild cell swelling 
were observed. C; Nrf2-MSC group: higher recovery and similarity 
to normal morphology of kidney. D; Renal histology (casts and 
tubular necrosis, quantified as number per high power field (HPF)) 
of cisplatin treated rats. Tubular necrosis and lesions included loss 
of brush border and epithelial cells, flattening, , and luminal cell 
debris. (Mean±SE, *: P<0.05, **: P<0.01 and ***: P<0.001) 
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Discussion  
The prevalence of acute kidney injury ranges from 5% of 
all hospitalized patients to 30 to 50% in critical care 
units.23 Application of some growth factors including 
insulin-like growth factor 1 (IGF-1), hepatocyte growth 
factor (HGF) and epidermal growth factor (EGF) for 
enhancement of tubular regeneration in experimental 
AKI has been one of the successful strategies.24,25 These 
growth factors rescue surviving tubular epithelial cells 
which consequently their regeneration repairs the injured 
kidneys. However, this approach requires plenty of 
surviving cells.24,25 Another critical strategy that involves 
a lot of studies in the world is the administration of 
MSCs. Various studies have shown that infusion of 
MSCs accelerates the recovery rate and prolongs survival 
of AKI animals.6,26-28 The mechanism of this treatment is 
based on the current theory about MSCs, stating that 
tissue stem cells replace dead tissue cells under 
physiologic conditions. Following tissue injury, 
mobilized stem cells replenish stem cell repertoire lost. 
When cell lost prevail stem cell repair, tissue injury 
occurs. Cytokines and chemokines secreted from injured 
tissue attract mobilized stem cells to repair site. 
Therefore, mesenchymal stem cells could not contribute 
in tissue repair and not enter organ in absence of injury.29 
Different studies have shown that MSCs exert their 
therapeutic effects via two distinct mechanisms including 
differentiation to target tissue cells and secretion of 
growth factors. Morigi et al. and Herrera et al. reported 
that MSC mediated protection is a result of the capability 
of MSCs to engraft into a damaged kidney.24,30 In 
addition, differentiation of MSCs into renal cell types has 
been observed after AKI. Moreover, Poulsom et al. 
showed that when Y chromosome containing MSCs are 
injected into female mouse with AKI, the transplanted 
MSCs are recruited into peritubular sites.31 In contrast, 
other studies have shown that the valuable effects of 
MSCs are mediated via paracrine activities. Some 
growth factors and chemokines, such as vascular 
endothelial growth factor (VEGF), basic fibroblast 
growth factor, monocyte-chemoattractant protein-1, 
HGF, and insulin-like growth factor-1 (IGF-1), are 
secreted by MSCs which enhance epithelial proliferation, 
modulate inflammation, or promote angiogenesis, and 
therefore are good candidates for therapy of AKI.6 
Many stresses are involved in AKI pathogenesis. Over 
50% of hospitalized cases of AKI are caused by renal 
ischemia.32 Ischemia is thought to create an inhospitable 
environment by inducing local expression of 
inflammatory cytokines that promote cell apoptosis.33 
Ischemia has two important components including 
hypoxia and serum deprivation.34 Also, it has been 
demonstrated that ischemia can cause oxidative stress.35 
In addition to tubular cells, these stresses cause apoptosis 
in transplanted MSCs.19,34 MSCs are more susceptible to 
death than other tissue cells.36,37 Therefore, not only 
MSCs alleviate the stresses, but they are died by stresses. 
Various factors such as strength and length of stresses, 
number of infused MSCs and the level of growth factors 
determine the outcome of this battle.  
Previously, we showed that overexpression of Nrf2 in 
mesenchymal stem cells reduces oxidative stress-induced 
apoptosis and cytotoxicity.19 Also, the protective role of 
Nrf2 has been previously shown by numerous 
studies.14,16,38 Higher surveillance rate of MSCs in 
stressful microenvironments could result in successful 
regeneration of the damaged tissue by the MSCs. Nrf2 is 
a transcription factor which activates expression of 
multiple antioxidants and detoxifying enzymes.39,40 
Therefore, Nrf2 overexpression in MSCs might decrease 
cytotoxic effect of stresses. Furthermore, previous 
studies, demonstrated that Nrf2 overexpression can 
increases the amount of some growth factors and 
detoxifying enzymes such as VEGF, HO-1 and SOD-1 
&2.19,41-44 As mentioned previously, administration of 
growth factors is one of the current strategies in AKI 
treatment. Consequently, Nrf2 overexpression in MSCs 
has a dual and synergistic protective effect on 
surveillance of MSCs which can result in successful 
treatment of AKI.  
Because of homology between human and rat Nrf2 
proteins,45 here we used the recombinant adenovirus 
vector harboring human Nrf2 coding sequence 
constructed in our previous study.19 Previously, we 
showed that the adenovirus mediated expression of Nrf2 
protein is transient. In addition, Nrf2 overexpression has 
no deleterious effect on differentiation capacity of MSCs 
into adipocytic, osteoblastic and chonderocytic lineages. 
In this study we showed that human Nrf2 could protect 
rat MSCs against cisplatin in vitro. This capability makes 
Nrf2 an excellent protein for improving transplantation 
process, especially for treatment of acute kidney injury. 
In this study, we hypothesized that Nrf2, as a potent 
cytoprotective transcription factor, could protect MSCs 
against stresses during transplantation. To verify this 
hypothesis, Nrf2-MSCs were transplanted into cisplatin-
induced AKI rats and their therapeutic efficacy was 
assessed by measuring blood urea nitrogen and creatinine 
concentration and morphologic analysis. 
AKI was diagnosed according to RIFLE criteria. These 
criteria include three categories of injury (Risk, Injury, 
and Failure with increasing severity) and two classes of 
kidney outcome (loss of function, and end-stage renal 
disease). Serum creatinine increases to 1.5-fold from 
baseline in the risk class. In the injury and failure classes, 
serum creatinine increases to 2.0 and 3.0-fold, 
respectively.46-49 In this study, it has been shown that 
while cisplatin treated rats developed failure class of 
AKI, but rats transplanted with Ad-MSCs and Nrf2-
MSCs developed injury and risk classes of AKI, 
respectively. It showed that MSC transplantation can 
reduce kidney damage and overexpression of Nrf2 in 
MSCs potentiates them against AKI.  
In the morphologic aspect, necrosis and apoptosis of 
tubular cells lead to tubular obstruction by cast 
formation. Casts are composed of shed epithelial cells 
and necrotic debris. Cytoskeletal disruption, ATP 
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depletion, loss of cell polarity, and cell-cell and cell-
matrix attachment are the consequences of ischemia.50-55 
These morphologic changes have been also seen in 
cisplatin treated rats. Because of the beneficial 
therapeutic effect of MSCs, morphological abnormalities 
decreased in Ad-MSCs rats. However, the Nrf2-MSCs 
were more effective in decreasing the morphological 
abnormalities comparing to the Ad-MSCs. Therefore, it 
could be deduced that Nrf2 overexpression protects 
MSCs from stress-related conditions in vivo.  
Nevertheless, a possible disadvantage of Nrf2 
overexpression is the risk of tumor progression.56 Recent 
studies have shown that an Nrf2 suppressor, Keap1, is 
often mutated in cancer cells resulting in a constitutive 
activation of Nrf2.57,58 In addition, it has been 
demonestrated that a hypoxic tumor microenvironment 
leads to increased transactivation of Nrf2.59 Considering 
the role of Nrf2 in regulating a battery of genes that act 
to detoxify cancer drugs and/or attenuate drug-induced 
oxidative stress, it is possible that Nrf2 overexpression 
may play role in increasing resistance to treatment in 
case of tumor progression.60-63 However, in the present 
study, no sign of tumorogenic transformational changes 
have been observed. 
 
Conclusion 
The obtained results showed that Nrf2 could inhibit 
apoptosis induction in MSCs transplanted into the 
cisplatin-induced AKI rats. In fact, despite rare reports 
on the existence of MSCs within the renal interstitium,64 
transplantation of MSCs satisfactorily contributed to 
restoring renal tubule structure and improving renal 
function, as reported by other studies.23,24,64-67 Therefore, 
MSCs probably exert their protective effect on cisplatin-
induced AKI in a paracrine manner, i.e. via production of 
growth factors and anti-inflammatory cytokines. 
Localization of MSCs in peritubular interstitial areas 
indicates that the MSCs acted by exerting paracrine 
activity.23 The Nrf2-MSCs produced higher amount of 
growth factors and therefore, can be more effective than 
the non-Nrf2 overexpressing Ad-MSCs in improvement 
of kidney functions. 
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